Table of Content

Executive Summary

1 Product Definition
1.1 Inclusions and Exclusions

2 Market Scope
2.1 Scope of Work
2.2 Key Questions Answered in the Report

3 Research Methodology
3.1 Global mRNA Vaccines and Therapeutics Market: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling

4 Market Overview
4.1 Market Definition
4.2 Current Landscape and Future Potential of mRNA-Based Vaccines
4.3 Market Footprint and Growth Potential
4.3.1 Global mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, 2020-2025
4.3.2 Global mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), $Million, 2025-2031

5 Industry Insights
5.1 Overview
5.2 Legal Requirements and Frameworks in the U.S.
5.2.1 Vaccines
5.2.1.1 Pre-Clinical and Clinical Development
5.2.1.2 Emergency Use Authorization (Public Health Emergencies)
5.2.1.3 Assessment of Manufacturing
5.2.1.4 Final Approval
5.2.2 Therapeutics
5.2.2.1 Clinical Trial Authorization
5.2.2.2 Marketing Authorization
5.2.2.3 Post-Authorization Regulations
5.3 Legal Requirements and Frameworks in Europe
5.3.1 Vaccines
5.3.2 Therapeutics
5.3.2.1 Centralized Procedure
5.3.2.2 Decentralized Procedure
5.3.2.3 Mutual-Recognition Procedure
5.3.2.4 National Procedure
5.4 Legal Requirements and Frameworks in Asia-Pacific
5.4.1 China
5.4.2 Japan

6 Market Dynamics
6.1 Overview
6.2 Impact Analysis
6.3 Market Drivers
6.3.1 Growing Cases of COVID-19 Globally
6.3.2 Favorable Regulatory Environment
6.3.3 Significant External Funding for the Development of mRNA-Based COVID-19 Vaccines
6.4 Market Restraints
6.4.1 Logistical Challenges Associated with mRNA-Based COVID-19 Vaccines
6.4.2 High Price Associated with mRNA-Based COVID-19 Vaccines
6.5 Opportunities
6.5.1 Growing Emphasis on Research and Development for Non-COVID-19 Applications

7 Competitive Landscape
7.1 Key Strategies and Developments
7.1.1 Synergistic Activities
7.1.2 Product Approvals and Commercialization
7.1.3 Funding
7.2 Market Share Analysis (by Company), 2020-2021

8 Global mRNA Vaccines and Therapeutics Market (by Application)
8.1 COVID-19 mRNA Vaccines
8.1.1 Overview
8.1.2 Commercialized Vaccines
8.1.2.1 mRNA-1273
8.1.2.1.1 Supply Agreements for mRNA-1273
8.1.2.2 BNT162b2
8.1.2.2.1 Supply Agreements for BNT162b2 (COMIRNATY)
8.1.3 Pipeline Vaccines
8.1.3.1 CVnCoV
8.1.3.2 LUNAR-COV19
8.1.3.3 MRT5500
8.1.3.4 DS-5670
8.2 Non-COVID-19 mRNA Vaccines
8.2.1 Overview
8.2.2 Oncology
8.2.3 Infectious Diseases
8.2.4 Other Diseases

9 Global mRNA Vaccines and Therapeutics Market (by mRNA Type)
9.1 Overview
9.2 COVID-19 (by mRNA Type)
9.2.1 Nucleoside-Modified mRNA (modRNA)
9.2.2 Unmodified mRNA
9.2.3 Self-Amplifying mRNA
9.3 Non-COVID-19 (mRNA Type)
9.3.1 Nucleoside-Modified mRNA (modRNA)
9.3.2 Unmodified mRNA
9.3.3 Self-Amplifying mRNA

10 Global mRNA Vaccines and Therapeutics Market (by Region)
10.1 Overview
10.2 North America
10.2.1 North America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 North America mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)
10.3 Europe
10.3.1 Europe mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 U.K.
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest-of-Europe
10.3.2 Europe mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)
10.4 Asia-Pacific
10.4.1 Asia-Pacific mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)
10.4.1.1 China
10.4.1.2 Japan
10.4.1.3 South Korea
10.4.1.4 Australia
10.4.1.5 Rest-of-Asia-Pacific
10.4.2 Asia-Pacific mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)
10.5 Latin America
10.5.1 Latin America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)
10.5.1.1 Brazil
10.5.1.2 Mexico
10.5.1.3 Rest-of-Latin America
10.5.2 Latin America mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)
10.6 Rest-of-the-World
10.6.1 Rest-of-the-World mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)
10.6.2 Rest-of-the-World mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)

11 Company Profiles
11.1 Overview
11.2 Arcturus Therapeutics Holdings Inc.
11.2.1 Company Overview
11.2.2 Role of Arcturus Therapeutics Holdings Inc. in the Global mRNA Vaccines and Therapeutics Market
11.2.3 Financials
11.2.4 Key Insights About Financial Health of the Company
11.2.5 SWOT Analysis
11.3 BioNTech SE
11.3.1 Company Overview
11.3.2 Role of BioNTech SE in the Global mRNA Vaccines and Therapeutics Market
11.3.3 Financials
11.3.4 Key Insights About Financial Health of the Company
11.3.5 SWOT Analysis
11.4 CureVac N.V.
11.4.1 Company Overview
11.4.2 Role of CureVac N.V. in the Global mRNA Vaccines and Therapeutics Market
11.4.3 Financials
11.4.4 Key Insights About Financial Health of the Company
11.4.5 SWOT Analysis
11.5 Daiichi Sankyo Company, Limited.
11.5.1 Company Overview
11.5.2 Role of Daiichi Sankyo Company, Limited. in the Global mRNA Vaccines and Therapeutics Market
11.5.3 Financials
11.5.4 Key Insights About Financial Health of the Company
11.5.5 SWOT Analysis
11.6 ethris GmbH
11.6.1 Company Overview
11.6.2 Role of ethris GmbH in Global mRNA Vaccines and Therapeutics Market
11.6.3 SWOT Analysis
11.7 GlaxoSmithKline plc
11.7.1 Company Overview
11.7.2 Role of GlaxoSmithKline plc in Global mRNA Vaccines and Therapeutics Market
11.7.3 Financials
11.7.4 Key Insights About Financial Health of the Company
11.7.5 SWOT Analysis
11.8 Gennova Biopharmaceuticals Ltd
11.8.1 Company Overview
11.8.2 Role of Gennova Biopharmaceuticals Ltd in Global mRNA Vaccines and Therapeutics Market
11.8.3 SWOT Analysis
11.9 Moderna, Inc.
11.9.1 Company Overview
11.9.2 Role of Moderna, Inc. in the Global mRNA Vaccines and Therapeutics Market
11.9.3 Financials
11.9.4 Key Insights About Financial Health of the Company
11.9.5 SWOT Analysis
11.1 Pantherna Therapeutics GmbH
11.10.1 Company Overview
11.10.2 Role of Pantherna Therapeutics GmbH in Global mRNA Vaccines and Therapeutics Market
11.10.3 SWOT Analysis
11.11 Providence Therapeutics
11.11.1 Company Overview
11.11.2 Role of Providence Therapeutics in Global mRNA Vaccines and Therapeutics Market
11.11.3 SWOT Analysis
11.12 Silence Therapeutics
11.12.1 Company Overview
11.12.2 Role of Silence Therapeutics in the Global mRNA Vaccines and Therapeutics Market
11.12.3 Financials
11.12.4 Key Insights About Financial Health of the Company
11.12.5 SWOT Analysis
11.13 Translate Bio
11.13.1 Company Overview
11.13.2 Role of Translate Bio in the Global mRNA Vaccines and Therapeutics Market
11.13.3 Financials
11.13.4 Key Insights About Financial Health of the Company
11.13.5 SWOT Analysis
11.14 VERSAMEB AG
11.14.1 Company Overview
11.14.2 Role of VERSAMEB AG in the Global mRNA Vaccines and Therapeutics Market
11.14.3 SWOT Analysis
11.15 Verve Therapeutics, Inc.
11.15.1 Company Overview
11.15.2 Role of Verve Therapeutics, Inc. in the Global mRNA Vaccines and Therapeutics Market
11.15.3 SWOT Analysis
 



List of Tables
Table 6.1: Likert Scale
Table 6.2: Impact Analysis of Market Drivers
Table 6.3: Impact Analysis of Market Restraints
Table 8.1: mRNA Vaccines and Therapeutics for Oncology (Pipeline)
Table 8.2: mRNA Vaccines and Therapeutics for Infectious Diseases (Pipeline)
Table 8.3: mRNA Vaccines and Therapeutics for Other Diseases (Pipeline)


List of Figures
Figure 1: Cumulative COVID-19 Cases (as of April 18, 2021)
Figure 2: Impact Analysis of Market Drivers and Market Challenges on Global mRNA Vaccines and Therapeutics Market
Figure 3: Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines (Commercialized), Q4 2020 Vs. Q4 2025
Figure 4: Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines (Pipeline), Q2 2021 Vs. Q4 2025
Figure 5: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 Vaccines (Pipeline), 2025 Vs. 2031
Figure 6: Global mRNA Vaccines and Therapeutics Market (by mRNA Type)
Figure 7: Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines (by Region), 2020-2025
Figure 8: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 Vaccines (by Region), 2025-2031
Figure 2.1: Global mRNA Vaccines and Therapeutics, Market Segmentation
Figure 3.1: Global mRNA Vaccines and Therapeutics Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Revenue for COVID-19 mRNA Vaccines, 2020-2025
Figure 4.2: Global mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), 2025-2031
Figure 5.1: Steps for Obtaining Marketing Authorization
Figure 5.2: Vaccine Development Stages
Figure 5.3: Steps for Obtaining EMA Approval for Vaccines
Figure 6.1: Cumulative COVID-19 Cases (as of April 18, 2021)
Figure 6.2: Logistical Challenge Pertaining to mRNA-Based COVID-19 Vaccines
Figure 7.1: Share of Key Developments and Strategies, January 2018-March 2021
Figure 7.2: Share of Synergistic Activities (by Company), January 2018-March 2021
Figure 7.3: Share of Product Approvals and Commercialization (by Company), January 2018-March 2021
Figure 7.4: Share of Funding (by Company), January 2018-March 2021
Figure 7.5: Market Share Analysis for Global mRNA Vaccines and Therapeutics Market, 2020 and 2021
Figure 8.1: Global Revenue for COVID-19 mRNA Vaccines, $Million, 2020-2025
Figure 8.2: Global Revenue for COVID-19 mRNA Vaccines (Commercialized), $Million, Q4 2020-Q4 2025
Figure 8.3: Global Revenue for COVID-19 mRNA Vaccines (mRNA-1273), $Million, Q4 2020-Q4 2025
Figure 8.4: Global Revenue for COVID-19 mRNA Vaccines (BNT162b2), $Million, Q4 2020-Q4 2025
Figure 8.5: Expected Revenue from mRNA-Based COVID-19 Vaccines (Pipeline), $Million, Q4 2020-Q4 2025
Figure 8.6: Global Estimated Revenue for CVnCoV, $Million, Q2 2021- Q4 2025
Figure 8.7: Global Estimated Revenue for LUNAR-COV19, $Million, Q3 2022-Q4 2025
Figure 8.8: Global Estimated Revenue for MRT5500, $Million, Q4 2022-Q4 2025
Figure 8.9: Global Estimated Revenue for DS-5670, $Million, Q4 2022-Q4 2025
Figure 8.10: Global mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)
Figure 8.11: Global mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), 2025-2031
Figure 8.12: Global mRNA Vaccines and Therapeutics Market (Oncology), $Million, 2025-2031
Figure 8.13: Global mRNA Vaccines and Therapeutics Market (Infectious Diseases), $Million, 2025-2031
Figure 8.14: Global mRNA Vaccines and Therapeutics Market (Other Diseases), $Million, 2025-2031
Figure 9.1: Global mRNA Vaccines and Therapeutics Market (by mRNA Type)
Figure 9.2: Global mRNA Vaccines and Therapeutics Market for COVID-19 (Nucleoside-Modified mRNA), $Million, Q42020-Q42025
Figure 9.3: Global mRNA Vaccines and Therapeutics Market for COVID-19 (Unmodified mRNA), $Million, Q2 2021-Q4 2025
Figure 9.4: Global mRNA Vaccines and Therapeutics Market for COVID-19 (Self-Amplifying mRNA), $Million, Q3 2022-Q4 2025
Figure 9.5: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 (Nucleoside-Modified mRNA), $Million, 2025-2031
Figure 9.6: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 (Unmodified mRNA), $Million, 2025-2031
Figure 9.7: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 (Self-Amplifying mRNA), $Million, 2029-2031
Figure 10.1: Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines (by Region), 2020 and 2025
Figure 10.2: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 Vaccines (by Region), 2025 and2031
Figure 10.3: North America: Market Dynamics
Figure 10.4: North America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020 vs. Q4 2025
Figure 10.5: North America mRNA Vaccines and Therapeutics Market (COVID-19 Vaccines), (by Country), $Million, Q4 2020 vs. Q4 2025
Figure 10.6: U.S. mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
Figure 10.7: Canada mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
Figure 10.8: North America mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), $Million, 2025-2031
Figure 10.9: Europe: Market Dynamics
Figure 10.10: Europe mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
Figure 10.11: Europe mRNA Vaccines and Therapeutics Market (COVID-19 Vaccines), (by Country), $Million, Q4 2020 vs. Q4 2025
Figure 10.12: Germany mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
Figure 10.13: France mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
Figure 10.14: U.K. mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
Figure 10.15: Italy mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
Figure 10.16: Spain mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
Figure 10.17: Rest-of-Europe mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2020-Q4 2025
Figure 10.18: Europe mRNA Vaccines and Therapeutics (by Non-COVID-19 Vaccines), $Million, 2025-2031
Figure 10.19: Asia-Pacific: Market Dynamics
Figure 10.20: Asia-Pacific mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
Figure 10.21: Asia-Pacific mRNA Vaccines and Therapeutics Market (COVID-19 Vaccines), (by Country), $Million, Q1 2021 vs. Q4 2025
Figure 10.22: China mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q2 2021-Q4 2025
Figure 10.23: Japan mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2021-Q4 2025
Figure 10.24: South Korea mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q2 2021-Q4 2025
Figure 10.25: Australia mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2021-Q4 2025
Figure 10.26: Rest-of-Asia-Pacific mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2021-Q4 2025
Figure 10.27: Asia-Pacific mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), $Million, 2026-2031
Figure 10.28: Latin America: Market Dynamics
Figure 10.29: Latin America mRNA Vaccines and Therapeutics Market (COVID-19 Vaccines), (by Country), $Million, Q1 2021 vs. Q4 2025
Figure 10.30: Latin America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
Figure 10.31: Brazil mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2021-Q4 2025
Figure 10.32: Mexico mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2021-Q4 2025
Figure 10.33: Rest-of-Latin America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2021-Q4 2025
Figure 10.34: Latin America mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), $Million, 2026-2031
Figure 10.35: Rest-of-the-World mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
Figure 10.36: Rest-of-the-World mRNA Vaccines and Therapeutics (by Non-COVID-19 Vaccines), $Million, 2026-2031
Figure 11.1: Total Number of Companies Profiled
Figure 11.2: Arcturus Therapeutics Holdings Inc.: Pipeline Portfolio
Figure 11.3: Arcturus Therapeutics Holdings Inc.: Overall Financials, 2018-2020
Figure 11.4: Arcturus Therapeutics Holdings Inc.: R&D Expenditure, 2018-2020
Figure 11.5: Arcturus Therapeutics Holdings Inc.: SWOT Analysis
Figure 11.6: BioNTech SE: Product Portfolio
Figure 11.7: BioNTech SE: Pipeline Portfolio
Figure 11.8: BioNTech SE: Overall Financials, 2018-2020
Figure 11.9: BioNTech SE: Revenue (by Segment), 2018-2020
Figure 11.10: BionNTech SE: R&D Expenditure, 2018-2020
Figure 11.11: BioNTech SE: SWOT Analysis
Figure 11.12: CureVac N.V.: Pipeline Portfolio
Figure 11.13: CureVac N.V.: Overall Financials, 2018-2019
Figure 11.14: CureVac N.V.: Revenue (by Region), 2018-2019
Figure 11.15: CureVac N.V.: R&D Expenditure, 2018-2019
Figure 11.16: CureVac N.V.: SWOT Analysis
Figure 11.17: Daiichi Sankyo Company, Limited: Pipeline Portfolio
Figure 11.18: Daiichi Sankyo Company, Limited: Overall Financials, 2017-2019
Figure 11.19: Daiichi Sankyo Company, Limited.: Revenue (by Segment), 2017-2019
Figure 11.20: Daiichi Sankyo Company, Limited.: Revenue (by Region), 2017-2019
Figure 11.21: Daiichi Sankyo Company, Limited: R&D Expenditure, 2017-2019
Figure 11.22: Daiichi Sankyo Company, Limited.: SWOT Analysis
Figure 11.23: ethris GmbH: Pipeline Portfolio
Figure 11.24: ethris GmbH: SWOT Analysis
Figure 11.25: GlaxoSmithKline plc: Pipeline Portfolio
Figure 11.26: GlaxoSmithKline plc: Overall Financials, 2018-2020
Figure 11.27: GlaxoSmithKline plc: Revenue (by Segment), 2018-2020
Figure 11.28: GlaxoSmithKline plc: Revenue (by Region), 2018-2020
Figure 11.29: GlaxoSmithKline plc: R&D Expenditure, 2018-2020
Figure 11.30: GlaxoSmithKline plc: SWOT Analysis
Figure 11.31: Gennova Biopharmaceuticals Ltd: Pipeline Portfolio
Figure 11.32: Gennova Biopharmaceuticals Ltd: SWOT Analysis
Figure 11.33: Moderna, Inc.: Product Portfolio
Figure 11.34: Moderna, Inc: Pipeline Portfolio
Figure 11.35: Moderna, Inc.: Overall Financials, 2018-2020
Figure 11.36: Moderna, Inc.: Revenue (by Segment), 2018-2020
Figure 11.37: Moderna, Inc.: Revenue (by Region), 2020
Figure 11.38: Moderna, Inc.: R&D Expenditure, 2018-2020
Figure 11.39: Moderna, Inc.: SWOT Analysis
Figure 11.40: Pantherna Therapeutics GmbH: Pipeline Portfolio
Figure 11.41: Pantherna Therapeutics GmbH: SWOT Analysis
Figure 11.42: Providence Therapeutics: Pipeline Portfolio
Figure 11.43: Providence Therapeutics: SWOT Analysis
Figure 11.44: Silence Therapeutics: Pipeline Portfolio
Figure 11.45: Silence Therapeutics: Overall Financials, 2019-2020
Figure 11.46: Silence Therapeutics: Revenue (by Segment), 2019-2020
Figure 11.47: Silence Therapeutics: Revenue (by Region), 2019-2020
Figure 11.48: Silence Therapeutics: R&D Expenditure, 2019-2020
Figure 11.49: Silence Therapeutics: SWOT Analysis
Figure 11.50: Translate Bio: Pipeline Portfolio
Figure 11.51: Translate Bio: Overall Financials, 2018-2020
Figure 11.52: Translate Bio: R&D Expenditure, 2018-2020
Figure 11.53: Translate Bio: SWOT Analysis
Figure 11.54: VERSAMEB AG: Pipeline Portfolio
Figure 11.55: VERSAMEB AG: SWOT Analysis
Figure 11.56: Verve Therapeutics, Inc.: Pipeline Portfolio
Figure 11.57: Verve Therapeutics, Inc.: SWOT Analysis